The PPARγ Agonist Rosiglitazone Enhances the Radiosensitivity of Human Pancreatic Cancer Cells

PURPOSE: As radiation therapy is widely used for the management of pancreatic cancer, identifying novel targets to improve the radiosensitivity of cancer cells is beneficial. Rosiglitazone, a specific peroxisome proliferator-activated receptor γ (PPARγ) agonist, has an inhibitory effect on various t...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Drug Des Devel Ther
Auteurs principaux: Wang, Zhenyu, Shen, Wenhao, Li, Xugang, Feng, Yang, Qian, Kun, Wang, Gaoren, Gao, Yiying, Xu, Xiaohui, Zhang, Shuyu, Yue, Ling, Cao, Jianping
Format: Artigo
Langue:Inglês
Publié: Dove 2020
Sujets:
Original Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7410396/
https://ncbi.nlm.nih.gov/pubmed/32801648
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S242557
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires